Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease

PR Kac, F Gonzalez-Ortiz, J Simrén, N Dewit… - Alzheimer's Research & …, 2022 - Springer
Background Blood phosphorylated tau (p-tau) forms are promising Alzheimer's disease (AD)
biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) …

Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy

MJ Grothe, A Moscoso, NJ Ashton, TK Karikari… - Neurology, 2021 - AAN Enterprises
Objective To study CSF biomarkers of Alzheimer disease (AD) analyzed by fully automated
Elecsys immunoassays compared to neuropathologic gold standards and to compare their …

Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition

SL Risacher, N Fandos, J Romero, I Sherriff… - Alzheimer's & Dementia …, 2019 - Elsevier
Introduction We investigated the relationship of plasma amyloid beta (Aβ) with cerebral
deposition of Aβ and tau on positron emission tomography (PET). Methods Forty-four …

Brain amyloid-β deposition and blood biomarkers in patients with clinically diagnosed Alzheimer's disease

WW Li, YY Shen, DY Tian, XL Bu… - Journal of …, 2019 - content.iospress.com
Brain amyloid-(A) deposition is a hallmark to define Alzheimer's disease (AD). We
investigated the positive rate of brain amyloid deposition assessed with 11C-Pittsburgh …

Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity

MY Chun, H Jang, HJ Kim, JP Kim… - Frontiers in Aging …, 2023 - frontiersin.org
Background Early detection of β-amyloid (Aβ) accumulation, a major biomarker for
Alzheimer's disease (AD), has become important. As fluid biomarkers, the accuracy of …

Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline

M Bucci, K Chiotis, A Nordberg… - Molecular …, 2021 - nature.com
For early detection of Alzheimer's disease, it is important to find biomarkers with predictive
value for disease progression and clinical manifestations, such as cognitive decline …

Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease

J Spiegel, E Pirraglia, RS Osorio… - Journal of …, 2016 - content.iospress.com
Cerebrospinal fluid (CSF) measures of phosphorylated-tau (P-tau) 231 and P-tau181 are
two biomarkers for the identification of tau pathology as related to Alzheimer's disease (AD) …

[HTML][HTML] Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease

S Fossati, JR Cejudo, L Debure, E Pirraglia… - Alzheimer's & Dementia …, 2019 - Elsevier
Introduction Plasma tau may be an accessible biomarker for Alzheimer's disease (AD), but
the correlation between plasma and cerebrospinal fluid (CSF) tau and the value of …

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient …

NR Barthélemy, RJ Bateman, C Hirtz, P Marin… - Alzheimer's research & …, 2020 - Springer
Background Cerebrospinal fluid biomarker profiles characterized by decreased amyloid-
beta peptide levels and increased total and phosphorylated tau levels at threonine 181 …

Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Aβ1–42 proteins to phosphorylated tau protein

H Hampel, A Goernitz, K Buerger - Brain research bulletin, 2003 - Elsevier
Advances have been made to establish biological markers of Alzheimer's disease (AD).
Measurement of total tau (t-tau) and beta-amyloid1–42 (Aβ1–42) in the cerebrospinal fluid …